22 results
POS AM
EFTR
eFFECTOR Therapeutics Inc
29 Mar 24
Prospectus update (post-effective amendment)
2:51pm
criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit … clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up
POS AM
EFTR
eFFECTOR Therapeutics Inc
17 Mar 22
Prospectus update (post-effective amendment)
7:18pm
patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, our … at which we can recruit patients to participate in our trials, as well as completion of requiredfollow-up
periods. The eligibility
criteria of our
POS AM
EFTR
eFFECTOR Therapeutics Inc
17 Mar 22
Prospectus update (post-effective amendment)
7:11pm
ability to recruit clinical trial investigators with the appropriate competencies and experience, our ability to obtain and maintain patient consents … is and will likely continue to be costly. The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate
424B3
zvhcqakandmiaefq3
2 Feb 22
Prospectus supplement
4:52pm
424B3
9n1ma8wu b8i
5 Oct 21
Prospectus supplement
4:24pm
424B3
el5eih99nj814ofzbz7
10 Aug 21
Prospectus supplement
5:11pm
S-4/A
t5tej5a4ayob7bfze
19 Jul 21
Registration of securities issued in business combination transactions (amended)
5:21pm
S-4
9iecuaemzq2f
14 Jun 21
Registration of securities issued in business combination transactions
5:10pm
8-K
EX-99.3
um1znht1q
27 May 21
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust
8:27am
8-K
EX-99.2
rx11vgo33 233mde556n
27 May 21
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust
8:27am
425
EX-99.3
2qr6ojx
27 May 21
Business combination disclosure
8:25am
425
EX-99.2
jwuvuyjb5jshyg5y10yw
27 May 21
Business combination disclosure
8:25am
10-K
bhh2po 4cgpx7ens7vn
29 Mar 21
Annual report
4:18pm
424B4
zc7delb5w uym
11 Jan 21
Prospectus supplement with pricing info
4:30pm